Idioma:

Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients

Quintana-Gallego, Esther ; Lopez-Campos, Jose Luis ; Calero, Carmen ; Dapena, Francisco Javier

Medicina clinica, 2014-01, Vol.142 (2), p.59 [Periódico revisado por pares]

Spain

Sem texto completo

Citações Citado por

Enviar para

Título:
Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients
Autor: Quintana-Gallego, Esther ; Lopez-Campos, Jose Luis ; Calero, Carmen ; Dapena, Francisco Javier
Assuntos: Administration, Inhalation ; Body Mass Index ; Child ; Child, Preschool ; Colistin - administration & dosage ; Colistin - analogs & derivatives ; Colistin - pharmacology ; Colistin - therapeutic use ; Cross-Over Studies ; Cystic Fibrosis - microbiology ; Drug Resistance, Bacterial ; Female ; Forced Expiratory Volume ; Humans ; Lung - microbiology ; Male ; Nebulizers and Vaporizers ; Patient Satisfaction ; Pseudomonas aeruginosa - drug effects ; Sputum - microbiology ; Surveys and Questionnaires ; Tobramycin - administration & dosage ; Tobramycin - pharmacology ; Tobramycin - therapeutic use ; Treatment Outcome
É parte de: Medicina clinica, 2014-01, Vol.142 (2), p.59
Descrição: To compare the efficacy, safety and treatment satisfaction with inhaled colistin versus tobramycin in the cure of chronic Pseudomonas colonization in cystic fibrosis patients. A quasi-experimental open paired data trial in which patients with cystic fibrosis and chronic colonization by Pseudomonas aeruginosa were included. Patients performed 2 periods of 6 consecutive months of nebulized antibiotics: inhaled tobramycin at a dose of 300 mg/12 h (Pari LC Plus(®)) and colistimethate (I-neb(®)) at a dose of 1 MIU twice a day. Visits were made monthly and at the beginning and the end of each period; we evaluated the body mass index, lung function, number of exacerbations and sputum microbiology. Patient satisfaction was assessed with 2 questionnaires of satisfaction on the treatment and the inhalation devices. A group of 25 patients (8 men and 6 under 14 years) with a mean age of 21.4 (7.2) years and 59.8 (21.1) % of forced expiratory volume in one second (FEV1) were included. During the second period, clinical benefits were obtained in terms of lung function with an FEV1 gain of 5% at 6 months of treatment and reducing the number of exacerbations (1.84 [1.2] vs 0.8 [0.8]; P=.001). The questionnaire score was higher in period 2. Colistimethate sodium administered through the misting system I-neb(®) provides clinical benefits in terms of exacerbations and improvement of lung function and patient satisfaction for the nebulized antibiotic treatment.
Editor: Spain
Idioma: Espanhol

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients

Quintana-Gallego, Esther ; Lopez-Campos, Jose Luis ; Calero, Carmen ; Dapena, Francisco Javier

Spain

Buscando em bases de dados remotas. Favor aguardar.